Status:
TERMINATED
Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel
Lead Sponsor:
Pack Health
Collaborating Sponsors:
Novartis
Ohio State University Comprehensive Cancer Center
Conditions:
Lymphoma, Large B-Cell, Diffuse
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The aim of this non-interventional multi-center study is to evaluate quality of life (QOL) and other patient reported outcomes (PROs) among adults with diffuse large b-cell lymphoma (DLBCL) following ...
Eligibility Criteria
Inclusion
- Adults aged 18 and older
- Able to read, speak and consent in English
- Diagnosis of diffuse large b-cell lymphoma
- Confirmed treatment with tisagenlecleucel (Kymriah)
- Internet access via smartphone, tablet, a computer, or another device with the capacity to receive calls, texts, or e-mails, as well as the electronic study assessments.
Exclusion
- Individuals who are terminally ill, defined as individuals identified by their physician as likely having 6 months or less to live, or those individuals transitioned to comfort measures only (meaning only supportive care measures without curative focused treatment)
- Individuals for whom there is documentation of inability to provide consent in the medical record
Key Trial Info
Start Date :
January 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 13 2022
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT05199961
Start Date
January 25 2022
End Date
September 13 2022
Last Update
May 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210